Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Conditions:   Pancreatic Ductal Adenocarcinoma;   Refractory Non-Small Cell Lung Cancer Interventions:   Drug: Daratumumab;   Biological: KRAS vaccine;   Drug: Nivolumab Sponsors:   Georgetown University;   Bristol-Myers Squibb;   Janssen, LP;   Targovax ASA Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials